SunWay Biotech Co

SunWay Biotech Co FCF/Debt

The Free Cash Flow to Debt Ratio of SunWay Biotech Co (1271.TWO) as of Oct 17, 2026 is 29.07 %. In the previous year, Free Cash Flow to Debt Ratio was 13.30 % — a change of 118.52% (higher).

FCF/Debt

29.07 %

YoY

118.52%

Last updated:

Free Cash Flow to Debt Ratio of SunWay Biotech Co is 2025 29.07 % . Free Cash Flow to Debt Ratio of SunWay Biotech Co was 2024 13.30 % . It decreases by 118.52% higher compared to the previous year.

The SunWay Biotech Co FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2020
1,062.88 TWD
Jan 1, 2021
729.77 TWD
Jan 1, 2022
56.06 TWD
Jan 1, 2023
3.21 TWD
Jan 1, 2024
13.30 TWD
Jan 1, 2025
29.07 TWD
The SunWay Biotech Co FCF/Debt history
YEARFCF/DebtYoY
29.07 %+118.52%
13.30 %+314.38%
3.21 %-94.27%
56.06 %-92.32%
729.77 %-31.34%
1,062.88 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SunWay Biotech Co Stock analysis

What does SunWay Biotech Co do? SunWay Biotech Co Ltd is a pharmaceutical company based in Taipei City, Taiwan. The company went public on January 18, 2021, with its ticker listed as 1271.TWO and ISIN TW0001271005. SunWay Biotech focuses on the research, development, manufacture, and sale of health food products, particularly those derived from red yeast. The company's primary products include Lactobacillus paracasei subsp. paracasei NTU 101 and Monascus purpureus NTU 568, which are marketed for their health benefits. These products are designed to support digestive health, improve the bacterial ecology of the digestive tract, regulate immunity, and address allergies. SunWay Biotech operates in both domestic and international markets, distributing its products globally. The company's website is https://sunway.cc/, where further information about its offerings can be found. SunWay Biotech is categorized under the Health Care sector, specifically within the Pharmaceuticals industry. The company's business model centers on the production and sale of health food supplements, emphasizing natural ingredients and their functional benefits. It does not provide information on specific founding year, key personnel, or financial figures beyond its IPO date. The company's activities are strictly limited to the development and distribution of health food products without mention of additional services or product lines. SunWay Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SunWay Biotech Co stock

Free Cash Flow to Debt Ratio of SunWay Biotech Co is 29.07 % in 2025.

Free Cash Flow to Debt Ratio of SunWay Biotech Co changed from 13.30 % to 29.07 %, representing a 118.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio SunWay Biotech Co since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's SunWay Biotech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — SunWay Biotech Co

All Key Metrics — SunWay Biotech Co